Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 500KG/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Azilsartan (INN, codenamed TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension that was developed by Takeda.
It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN, codenamed TAK-491). On 25 February 2011, the U.S. Food and Drug Administration (FDA) approved azilsartan medoxomil for the treatment of high blood pressure in adults. On March 8, 2012, Health Canadaapproved the drug for mild to moderate essential hypertension.
Active metabolites :As a precursor of the temple, sand ester, on April 28, 2010, Japanese Takeda pharmaceuticals (Takeda) research and development of the drug has completed phase iii trial, in 2011 the FDA approval, the drug as an angiotensin II receptor antagonist, can be used alone or in combination with other blood pressure medicines, is seen as the next generation of candesartan ester products.
Application:Is a is in the treatment of hypertension in the research and development of angiotensin II receptor antagonist medicine, used in the treatment of hypertension, is currently the only at the end of the clinical angiotensin II receptor antagonist medicine statins (sand).
